We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
The Minister of Health refused to grant data exclusivity to data from Epicept’s phase I and phase II clinical trials because CEPLENE is not an “innovative drug”
